Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
June 13 (Reuters) - Moderna's shares (MRNA.O), opens new tab fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs the U.S. Centers for Disease Control and Prevention's recommendation before it is made available for the age group. It is already approved for use in adults aged 60 or older.
The biotech's stock extended its decline into the second session, following the appointment of the new panel late Wednesday. Some of the new appointees have openly expressed anti-vaccine views, including against the mRNA vaccine technology on which Moderna's shots are based.
Earlier this week, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the panel, known as the Advisory Committee on Immunization Practices (ACIP), saying it would "re-establish public confidence in vaccine science" - a move health experts warn could undermine public confidence in available vaccines.
The ACIP advises the CDC on who should get the shots after they are approved by the U.S. Food and Drug Administration.
The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view," said William Blair analyst Myles Minter.
U.S.-listed shares of GSK (GSK.L), opens new tab and Pfizer (PFE.N), opens new tab fell marginally and those of smaller Novavax (NVAX.O), opens new tab were down 1.7% at $7.03 in premarket trade.
The CDC currently recommends Moderna's vaccine for adults aged 75 and older, as well as for at-risk adults aged 60 to 74.
In April, the ACIP recommended the use of approved RSV vaccines in at-risk adults aged 50 to 59. However, the CDC is yet to sign off on the recommendation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
35 minutes ago
- Medical News Today
Celiac disease: Is an easier way to diagnose it on the horizon?
Could a blood test diagnose celiac disease without the need to trigger symptoms? Image credit: Alvaro Lavin/Stocksy. Celiac disease has to do with an abnormal immune response of the body to gluten. Experts are interested in the best ways to test for celiac disease. A recent study discovered that a blood test called WBAIL-2 could aid in diagnosing celiac disease and even contribute to biopsy-free diagnosis. Celiac disease occurs when someone's immune system responds abnormally to gluten. Efforts to improve celiac disease diagnosis are ongoing. A study recently published in Gastroenterology evaluated the effectiveness of using a blood test that measures the cytokine interleukin-2 to diagnose celiac disease. The study's results indicated that the test to be highly effective for celiac disease diagnosis, even for people following a gluten-free diet. The test could offer another option to help with celiac disease diagnosis — importantly, one that would not require triggering symptoms to confirm the disease. The authors of the current study note that there is often a delay or lack of diagnosis when it comes to celiac disease. Diagnosis usually involves people having to eat gluten and get biopsies of the small intestine. Celiac disease also has to do with the response of a group of immune cells, CD4+ gluten-specific T-cells. For this study, researchers wanted to determine if the use of a blood test that measures interleukin-2 — a protein produced by some T-cells — release could help to accurately diagnose celiac disease. This research involved a total of 181 adult participants between 18 and 75 years old. Of these participants, 88 had celiac disease, and others were controls. Among controls, 32 participants had a non-celiac gluten sensitivity and were on a gluten-free diet. The rest were healthy controls who did not have gluten sensitivity. All participants provided blood samples, and researchers collected data on medications and medical history. A subset of participants, including healthy controls, participants with non-celiac gluten sensitivity, and treated celiac disease, went on a gluten-free diet for four weeks or more and then consumed gluten for 'a single-dose open-label gluten challenge.' Some participants with treated celiac disease also did an oral gluten challenge that lasted 3 days. If participants underwent the oral gluten challenge, they used diaries to keep track of their symptoms. Researchers utilized a blood test called a WBAIL-2 assay, which measures the release of interleukin-2 in vitro after adding gluten peptides. In general, the test was able to effectively confirm celiac disease, with higher concentrations and fold change of interleukin-2 in participants who had celiac disease. However, the results were less sensitive for participants with a certain, less common genotype. Analysis results also found that the WBAIL-2 assay correlated with age and the number of years participants had been following a gluten-free diet. Next, researchers tested participants' serum levels of interleukin-2 after they did an oral gluten challenge. The levels of interleukin-2 were higher for participants with celiac disease following the oral gluten challenge. Researchers also found these levels 'positively correlated with the WBAIL-2 results.' So, if the levels of interleukin-2 were elevated on one test, they were also elevated on the other. They also tested how the WBAIL-2 results related to the presence of gluten-specific T cells, which were higher among participants with celiac disease. They did find that the presence of these cells, as well as activated versions of these cells, correlated with the WBAIL-2 test. The researchers further found that gluten-specific T cells, activated versions of these cells, and WBAIL-2 increased after participants underwent a gluten challenge. However, one participant had lower gluten-specific CD4+ T cells and a lower WBAIL-2 test on day six. Researchers also looked at treated celiac disease participants and how the tests related to their symptoms after gluten exposure. When it came to gluten-specific T-cells, their frequency was higher in participants who experienced vomiting. The measurement of serum interleukin-2 following the gluten tolerance test was also elevated, as was the WBAIL-2 level. The WBAIL-2 level was also increased greatly for one participant who did not experience vomiting but did report severe tiredness. Further analysis also suggested that activated gluten-specific CD4+ T cells are the cells that lead to gluten-induced production of interleukin-2. The results suggest that the WBAIL-2 assay can help with celiac disease diagnosis, even when people are already following a gluten-free diet. There are some limitations to this study. For one thing, it was performed out of one area, most participants were female, and there were strict inclusion criteria, so it has a limited generalizability. It also had small sample sizes for some subgroups, which means more research may be particularly necessary in these subgroups. Since researchers did not test children or people taking immunosuppressants, more research is needed to see how well this testing method would work in these populations. Researchers also acknowledge an untested 'reproducibility across laboratories.' More research is thus needed before the WBAIL-2 assay can really be used in the clinical setting. Further, the authors did not examine the cost-effectiveness of the WBAIL-2 test and how well this would stack up against current ways of diagnosing celiac disease. Then, the test was not as accurate for some participants with a specific genotype, which means it might not work for everyone. However, the number of participants with this genotype was very small in this study, and it is possible that the level of interleukin-2 response of some participants with this genotype was just not able to be detected by the test. Overall, more research is required regarding this subtype of individuals and the use of this test. Ian Storch, DO, an osteopathic physician specializing in gastroenterology and internal medicine, and an American Osteopathic Association member, who was not involved in this study, spoke to Medical News Today about its findings. 'One limitation of this study is the poor performance in the DQ8 genetic arm, which makes up 10% of celiac patients. This will decrease the sensitivity and specificity for the control group or require HLA typing before the assay is run.' Researchers acknowledge that the serum analysis of interleukin-2 following a gluten challenge does not always line up with the results of the WBAIL-2 assay, which could have to do with the assays' differences. Shilpa Mehra Dang, MD, double board-certified in gastroenterology and internal medicine with Medical Offices of Manhattan and contributor to LabFinder, who was similarly not involved in this research, noted that 'we need to look at bigger samples to really see its clinical usefulness.' In addition to larger studies, research can also focus on more details regarding gluten-specific T cells. Celiac disease is a challenging condition to manage, and accurate diagnosis is important. Researchers suggest that examining WBAIL-2 and serum interleukin-2 after gluten consumption could allow people with celiac disease to not have to get biopsies done to confirm celiac diagnosis. The authors of this study also suggest that the WBAIL-2 assay could also become a first test among people following a gluten-free diet and help with symptom severity prediction. Storch said: 'I do not think that based on the data presented, removal of histology to confirm the diagnosis can be suggested.' Jeffrey D. Davis, DO, CMD, an osteopathic physician specializing in Family Medicine and Preventive Health and an American Osteopathic Association board member, who was not involved in the study, noted the following to MNT : 'I see potential for a commercially available rapid, simple, cost-effective laboratory test for physicians to use to assist in the accurate diagnosis of celiac disease. This study shows that especially in adults already on a gluten-free diet using this lab test versus currently available tests would improve our diagnostic capabilities for Celiac Disease. However, it would most likely be just another tool in our tool box to aid in the diagnosis along with other current diagnostic methods.'
Daily Mail
an hour ago
- Daily Mail
Surprising ingredient in dessert favorites that raises your risk of a heart attack
Cardiologists are warning of an often overlooked ingredient in desserts that can lead to high blood pressure if consumed in excess. Typically a garnish on cookies, bread and butter, soft pretzels, and caramel treats, coarse sea salt contains more sodium than its less expensive grocery store alternative. People enjoy the added crunch and marriage of savory and sweet in desserts, but people are inadvertently eating too much salt. Because coarse salt has larger crystals, it may feel less salty per bite, leading some people to use more than they would with fine salt. Excessive sodium intake is linked to high blood pressure, heart disease, stroke, and kidney problems. The body only needs a small amount of sodium to function properly. Sodium is an essential electrolyte that plays several critical roles in the body, including maintaining fluid balance and blood pressure, supporting nerve function, and enabling muscle contractions. Most Americans consume too much sodium, though – 3,300 mg per day on average, or about 40 percent more than the recommended 2,300mg limit. People tend to believe that coarse sea salt contains less sodium than standard fine salt, yet both contain about 40 percent sodium. Salt lurks everywhere in the Western diet, not just in processed meats, snack foods, but in unsuspecting foods, including breads, canned soups, frozen meals, cheese, sauces, and marinades. An estimated 89 percent of adults and around 94 percent of children consume too much sodium, according to the CDC. Eating too much salt is a major setup for high blood pressure. The World Health Organization also estimates that 1.9 million deaths globally each year can be attributed to eating too much salt. As sodium causes the body to retain fluids, blood volume and pressure on artery walls increase. High blood pressure is a significant risk factor for heart disease, stroke, kidney disease, and other serious health issues. Dr Brent Egan, an internist and vice president of cardiovascular health at the American Medical Association, said: 'It would take us about a little over 1,000 milligrams a day to get from where we are to where the recommendation would be for the upper limit.' 'And if we did that, we'd probably see a significant reduction in blood pressure, heart attack and stroke.' Roughly 116 million Americans have high blood pressure. Approximately 805,000 heart attacks occur each year, as well as 795,000 strokes. 'If someone has high blood pressure, heart disease, that type of thing, 1,500 milligrams is probably a better target, but for the general population that's really interested in limiting the burden of chronic disease, 2,300 milligrams is generally what is recommended,' Dr Egan said. Too much sodium also causes bloating – the uncomfortable feeling that the stomach is swollen and tight. Body parts like hands, feet, and ankles are likely to swell. And feelings of thirst take over due to dehydration. Too much salt before bed can also cause restless sleep. Studies suggest high-salt diets may alter cortisol (stress hormone) levels, which regulate sleep-wake cycles. A recent study by researchers at Vanderbilt University found that reducing daily salt intake by just one teaspoon is as effective as blood pressure medication. They tested high and low-salt diets on hundreds of patients, some of whom had high blood pressure, and found that cutting out a can of Heinz soup each day lowered people's blood pressure by six percent within a week. This reduction was comparable to that of thiazide diuretic hydrochlorothiazide, a popular blood pressure medication. 'Obviously we need some sodium—it's essential for life,' Dr Egan said. But 'here we are with an average intake of 3,400 milligrams. 'Now the body has to make a lot of adjustments, but we can get by with very little sodium,' he said, noting 'there's very little danger in this country that most people won't get enough sodium, even if they're eating those fresh foods and not processed foods. 'They'll still—for the most part—get more than sufficient sodium that the body needs,' said Dr. Egan. 'We live in a state of pretty much constant excess.'
Daily Mail
6 hours ago
- Daily Mail
The key to being happier, smarter and ageing better, by leading neuroscientist DR JOSEPH JEBELLI. An extraordinary scientfic breakthrough shows what part of modern life is destroying our brains - now his new book has the cure
You're sitting at your desk, trying to look busy, and your work isn't going well. OK, it's time to double down and try a bit harder... but for some reason your brain fails to ignite. It's just one of those things we all experience at work – and until recently, no one really understood how to kick-start the brain back into action.
